Tremeau Pharmaceuticals, Inc., a Cambridge, Mass.-based pharmaceutical company focused on providing non-opioid pain treatments for rare diseases, closed a $5.2m first equity round.
The funding will be used to advance Tremeau’s pipeline of non-opioid pain treatment candidates.
Led by Bradford C. Sippy, Chief Executive Officer, Tremeau is a new pharmaceutical company focused on providing non-opioid pain treatments for rare diseases and other unique patient conditions with no approved treatments. Its approach to acute and chronic pain in rare diseases is rooted in the mechanism of action, documented efficacy, and clinically differentiated profile of COX-2 selective NSAIDs.
The company’s TRM-201 (rofecoxib) is a cyclooxygenase-2 (COX-2) selective non-steroidal anti-inflammatory drug (NSAID) with an efficacy profile with granted orphan designation status for the treatment for hemophilic arthropathy. Rofecoxib is a non-narcotic analgesic, has no effect on bleeding time relative to placebo and is the only COX-2 selective NSAID approved in the U.S. to demonstrate a reduced risk of gastrointestinal bleeding versus a traditional NSAID in a controlled trial.
Tremeau plans to develop and commercialize rofecoxib for the orphan indication of the treatment of hemophilic arthropathy and subsequent niche patient segments with no approved treatments and where it could have a strong benefit to risk ratio versus other therapies.